• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Companies Collaborate to Collate Capital Project Benchmarking Costs


Lead company is seeking others to join the initiative.

Consultancy firm Linesight (London, UK) reports that it is leading a collaboration with major pharmaceutical companies on benchmarking data.

Merck, AstraZeneca, BMS, Pfizer, GSK, Ipsen, Viatris, Wuxi and others are participating in a global effort to collate capital project benchmarking costs, schedule intelligence and analysis in a central, independent, confidential fashion. Linesight reports that it is now seeking others to join this initiative.

“The more project data we collate, the more valuable it will be to the industry at large, which is why we are seeking further companies to get involved. This is a hugely significant initiative, and one which will have global impact for many years to come,” commented Nigel Barnes, Director of Life Sciences EMEA, Linesight.

Steve White, Leader of Global Estimating and Control at Merck, said, “Benchmarking data is essential to gauge the capital effectiveness of our projects both internally and externally with other pharmaceutical companies.”

Steve Townsend, Director Project Controls, Global Capital Projects, GSK added, “As we seek to continuously improve our project scoping and delivery, we must understand how we compare to our peers within the industry. Participating in this program offers us the necessary access to key, comparative data and should provide us with improved confidence.”

For further information on the program, contact lifesciences@linesight.com

Related Videos
Related Content